
Alzheimer’s drug requires strengthened pharmacovigilance approach
Ongoing real-world safety and effectiveness monitoring of the Alzheimer’s drug lecanemab is needed to protect patients long-term, drug safety researchers urge. A paper published by the Drug Safety Research Unit (DSRU) in the British Journal for Clinical …